BridgeBio Oncology Therapeutics (BBOT) Change in Acquisitions & Divestments (2024 - 2026)

BridgeBio Oncology Therapeutics has reported Change in Acquisitions & Divestments for 3 years, with the latest figure at $26.3 million in Q1 2026.

• Quarterly Change in Acquisitions & Divestments fell 34.28% year-over-year to $26.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $120.7 million (changed N/A YoY) and the FY2025 annual result came in at $157.9 million, up 400.44% from the prior year.
• Change in Acquisitions & Divestments retreated to $26.3 million in Q1 2026 per BBOT's latest filing, from $28.9 million in the prior quarter.
• Over five years, Change in Acquisitions & Divestments peaked at $40.0 million in Q1 2025 and troughed at $25.6 million in Q4 2024.
• A 3-year average of $30.2 million and a median of $27.6 million in 2025 frame the typical range for Change in Acquisitions & Divestments.
• The sharpest annual moves came in 2025 and 2026: Change in Acquisitions & Divestments increased 12.97% in 2025, then slumped 34.28% in 2026.
• Over 3 years, Change in Acquisitions & Divestments stood at $25.6 million in 2024, then climbed by 12.97% to $28.9 million in 2025, then decreased by 9.07% to $26.3 million in 2026.
• According to Business Quant data, Change in Acquisitions & Divestments over the past three periods registered $26.3 million, $28.9 million, and $40.0 million for Q1 2026, Q4 2025, and Q1 2025 respectively.